Table 1 Patient demographics and tumor characteristics.
Entire cohort | |||||
|---|---|---|---|---|---|
n = 226 | |||||
Training cohort | Validation cohort | ||||
n = 112 | n = 114 | P-value | |||
Sex | 0.669 | ||||
67 | (59.8%) | 65 | (57.0%) | ||
Female | 45 | (40.2%) | 49 | (43.0%) | |
Age, years | 62 | ± 10.8 | 56.5 | ± 8.15 | 0.1155 |
KPS score | 0.0165 | ||||
≥ 70 | 54 | (48.2%) | 73 | (64.0%) | |
< 70 | 58 | (51.8%) | 41 | (36.0%) | |
Presence of extracranial metastases | 0.0385 | ||||
No (brain only) | 19 | (17.0%) | 9 | (7.9%) | |
Yes (brain and other sites) | 93 | (83.0%) | 105 | (92.1%) | |
Status of primary tumor | 0.7956 | ||||
Controlled | 99 | (88.4%) | 102 | (89.5%) | |
Uncontrolled | 13 | (11.6%) | 12 | (10.5%) | |
Brain metastases, n | 0.0628 | ||||
1 | 46 | (42.0%) | 53 | (46.5%) | |
2 | 17 | (15.2%) | 29 | (25.4%) | |
3 | 12 | (10.7%) | 9 | (7.9%) | |
Extensive (≥ 4) | 37 | (32.1%) | 23 | (20.2%) | |
Maximum diameter of brain lesion* | 23 | ± 14.7 | 26 | ± 11.7 | 0.2034 |
History of systemic chemotherapy before brain metastases | 0.0164 | ||||
0 | 34 | (30.4%) | 15 | (13.2%) | |
1 | 28 | (25.0%) | 33 | (28.9%) | |
2 | 21 | (18.8%) | 26 | (22.8%) | |
3 | 14 | (12.5%) | 24 | (21.1%) | |
4 | 7 | (6.3%) | 11 | (9.6%) | |
≥ 5 | 8 | (7.1%) | 4 | (3.5%) | |
Time interval between diagnosis of primary tumor and brain metastases* | 0.0028 | ||||
Synchronous | 15 | (13.4%) | 3 | (2.6%) | |
Metachronous | 97 | (86.6%) | 111 | (97.4%) | |
Treatment of brain metastases from colorectal cancer | 0.2601 | ||||
WBRT alone | 42 | (37.5%) | 43 | (37.7%) | |
SRT alone | 24 | (21.4%) | 32 | (28.1%) | |
SRT + WBRT | 5 | (4.5%) | 6 | (5.3%) | |
Surgery + SRT | 11 | (9.8%) | 12 | (10.5%) | |
Surgery alone | 6 | (5.4%) | 3 | (2.6%) | |
Surgery + WBRT | 15 | (13.4%) | 17 | (14.9%) | |
Surgery + WBRT + SRT | 2 | (1.8%) | 0 | (0.0%) | |
Supportive care | 7 | (6.3%) | 1 | (0.9%) | |
